Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | May 2004 |
The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron
emission tomography (PET) scans.
PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with
stage III or stage IV non-small cell lung cancer and in healthy participants.
emission tomography (PET) scans.
PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with
stage III or stage IV non-small cell lung cancer and in healthy participants.
OBJECTIVES:
- Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV
non-small cell lung cancer (NSCLC) and in healthy participants.
- Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron
emission tomography in patients with stage III or IV NSCLC.
OUTLINE: This is a pilot study.
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body
dynamic scans comprising positron emission tomography.
Blood is collected during and after imaging to measure radioactivity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
- Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV
non-small cell lung cancer (NSCLC) and in healthy participants.
- Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron
emission tomography in patients with stage III or IV NSCLC.
OUTLINE: This is a pilot study.
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body
dynamic scans comprising positron emission tomography.
Blood is collected during and after imaging to measure radioactivity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Inclusion Criteria:
- Must meet 1 of the following criteria:
- Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
- Stage III or IV disease
- Clinically assessed with
- Healthy participant
Exclusion Criteria:
We found this trial at
1
site
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
Los Angeles, California 90095
(310) 825-5268
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
Click here to add this to my saved trials
